**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 29212**

**Manuscript Type: CASE REPORT**

**“*En bloc*” caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancer**

Sánchez-Velázquez *et al*. Caudate lobe resection after CRS and HIPEC

Patricia Sánchez-Velázquez, Nicolas Moosmann, Ingolf Töpel, Pompiliu Piso

**Patricia Sánchez-Velázquez, Pompiliu Piso**, Department of Surgery, Barmherzige Brüder Krankenhaus Regensburg, 93049 Regensburg, Germany

**Nicolas Moosmann,** Department of Oncology and Hematology, Barmherzige Brüder Krankenhaus Regensburg, 93049 Regensburg, Germany

**Ingolf Töpel,** Department of Vascular Surgery, Barmherzige Brüder Krankenhaus Regensburg, 93049 Regensburg, Germany

**Author contributions:** All authors reviewed and supervised the manuscript. Sánchez-Velázquez P wrote the main manuscript text and Piso P in collaboration with Moosmann N andTöpel I have supervised the design, develop and main content of the manuscript.

**Institutional review board statement:** This case report was approved by the Institutional Review Board standards.

**Informed consent statement:** The patient involved in this study gave her informed consent authorizing use and disclosure of her protected health information

**Conflict-of-interest statement:** The authors declare no conflict of interests.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Patricia Sánchez-Velázquez, MD**, Department of Surgery, Barmherzige Brüder Krankenhaus Regensburg, Prüfeningerstrasse 86, 93049 Regensburg, Germany. [patri\_sv5@hotmail.com](mailto:patri_sv5@hotmail.com)

**Telephone**: +49-941-3692205

**Received:** August 2, 2016

**Peer-review started:** August 2, 2016

**First decision:** August 29, 2016

**Revised:** September 10, 2016

**Accepted:** September 28, 2016

**Article in press:**

**Published online:**

**Abstract**

There are diverse protocols to manage patients with recurrent disease after primary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis. We describe a case of metachronous liver metastasis after CRS and HIPEC for colorectal cancer, successfully treated with a selective metastectomy and partial graft of the inferior vena cava. A 35-year-old female presented with a large tumour in the cecum and consequent colonic stenosis. After an emergency right colectomy, the patient received adjuvant chemotherapy. One year later she was diagnosed with peritoneal carcinomatosis, and it was decided to carry out a CRS/HIPEC. After 2 years of total remission, an isolated metachronous liver metastasis was detected by MRI surveillance. The patient underwent a third procedure including a caudate lobe and partial inferior vena cava resection with a prosthetic graft interposition, achieving an R0 situation. The postoperative course was uneventful and the patient was discharged on postoperative day 17 after the liver resection. At 18-mo follow-up after the liver resection the patient remained free of recurrence. In selected patients, the option of re-operation due to recurrent disease should be discussed. Even liver resection of a metachronous metastasis and an extended vascular resection are acceptable after CRS/HIPEC and can be considered as a potential treatment option to remove all macroscopic lesions.

**Key words:** Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Colorectal cancer; Liver resection; Liver metastasis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Treatment of liver recurrence after a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a great challenge.We report here the case of a young patient with metachronous liver metastases who was treated with a limited resection of segment I of the liver and vascular graft interposition of the inferior vena cava achieving a long-term survival. The surgical approach of these patients is extremely complicated and often requires complex major surgical procedures.

Sánchez-Velázquez P, Moosmann N, Töpel I, Piso P. “*En bloc*” caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancer. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Peritoneal carcinomatosis (PC) is the second most common presentation of metastatic colorectal cancer and is diagnosed in up to 4%-6% of these cases. Twenty five percent of these patients have the peritoneum as the only site of disseminated disease[1]. PC was traditionally considered the last stage of the disease and was associated with a poor prognosis so that patients were often relegated to palliative systemic therapies. In recent decades multimodal PC treatment has made great advances; cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic chemotherapy have shown promising results and have become standard therapy for PC patients in several countries[2-7]. Various studies have reported that patients undergoing CRS with total macroscopic cytoreduction and HIPEC may achieve prolonged overall survival and potentially even a complete cure in selected patients[4,8,9].

Up to 80% of patients with PC of colorectal origin treated with CRS and HIPEC are likely to recur[10,11]. In selected cases the possibility of a reoperation due to recurrence or even an extensive abdominal surgical procedure can be individually assessed. The data available on this approach show favourable long-term outcomes with similar morbidity and mortality to that of initial CRS/HIPEC[12-15]. Simultaneous or staged combined CRS and liver resections have also been performed with comparable morbidity and long-term results[16]. In this report we describe the case of a young female patient with metachronous liver metastasis after CRS and HIPEC for colorectal cancer successfully treated by a selective liver and vascular resection.

**CASE REPORT**

A 35-year-old female was referred to our emergency unit in February 2011, presenting with abdominal distension, pain, and vomiting for 3 d. Her medical history was only remarkable for asthma. Abdominal computed tomography (CT) was performed and revealed a large tumor in the cecum with consecutive colonic stenosis. The patient underwent an emergency right colectomy, and an R0 situation was achieved. Pathologic examination showed pT4a pN2a (4/22) cM0 poorly differentiated adenocarcinoma. Between March and August 2011 she received 12 cycles of adjuvant FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin). In February 2012 a CT scan identified lesions in the peritoneum with suspicions of peritoneal carcinomatosis. Our multidisciplinary tumour board decided on pursuing CRS with HIPEC. Abdominal exploration revealed widespread peritoneal carcinomatosis, especially in the pelvis and a large tumor mass in the left sub-diaphragmatic region with a peritoneal cancer index (PCI) of 14. Total parietal and diaphragmatic peritonectomy, proctocolectomy with an end ileostomy, terminal ileum resection, splenectomy, omentectomy, hysterectomy and bilateral salpingo-oophorectomy (CCR-0) were performed to remove the macroscopic tumor. HIPEC was carried out to treat the microscopic residual with mitomycin C, according to the closed-abdomen technique. The postoperative course was uneventful and the patient was duly discharged from hospital. At this time, no further chemotherapy was recommended as the patient had completed adjuvant chemotherapy after the first operation and a R0 situation was achieved*.* Adjuvant systemic chemotherapy, according to our institution protocols, is performed only in chemo naïve patients. From February 2012 until June 2014 the patient stayed free from recurrence. In July 2014 abdominal MRI surveillance revealed a solid tumor in segment 1 of the liver (Figure 1) so the patient underwent explorative laparotomy. During the procedure no evidence of a peritoneal recurrence was shown but many adhesions were found from the previous operations. A 4 cm tumor was identified in the caudate hepatic lobe infiltrating the inferior vena cava (IVC). The distal cava was mobilized towards the left renal vein and was divided at a level free of tumor (Figure 2A). Liver segment 1 was transected following the clamp-crushing technique and ICV cranial to the tumor was dissected and divided under the major suprahepatic trunks. Vascular continuity was restored using a prosthetic graft interpositionsutured with a running suture of prolene 5/0 onto the proximal and distal IVC (Figure 2B). The postoperative course was mainly uncomplicated except for right pleural effusion, initially managed conservatively with diuretic therapy, and later by thoracocentesis. The patient was finally discharged on the 17th postoperative day. Pathological examination revealed a poorly differentiated adenocarcinoma with identical immunohistochemical phenotype as previously. At this point it was decided not to continue with chemotherapy, as a CCR-0 situation had been surgically achieved and the patient had completed the 12-cycle adjuvant treatment in the past (Table 1). Eighteen months after metastasis resection of the liver and 4 years after CRS and HIPEC, the patient shows no evidence of neoplastic disease.

**DISCUSSION**

After initial CRS and HIPEC, recurrences are mostly intra-abdominal, even if complete cytoreduction is achieved[17]. Protocols differ among the different institutions, thus a number of different treatments are applied in high-volume centres, including chemotherapy, tumour debulking or re-do surgery for intraadominal metastasis.

The presence of synchronous liver metastases (LM) and PC was traditionally a contraindication for cytoreductive surgery. However, it has been shown that selected patients with low PCI and three or fewer LM can achieve prolonged survival if a liver resection is performed simultaneously[16,18]. A recent meta-analysis by Cuba et al. shows improved overall survival (OS) in patients who were treated with CRS and HIPEC and curative treatment of LM as compared to patients treated with modern systemic chemotherapy alone[19].

Nevertheless, it remains unclear which approach should be used in patients with isolated metachronous LM, as in our case report. Iterative cytoreductive surgery is feasible in cases of recurrence and appears to be worthwhile in terms of long-term outcomes[20]. The study by Sugarbaker and colleagues was on one of the largest series and included 70 patients with PC of colorectal origin[15]. This study showed that 53% of the patients had at least one reoperation after the initial cytoreduction. The overall survival of patients with repeated surgery approach was significantly longer (39 mo *vs* 20 mo). Brouquet *et al*[13] reported on a cohort of 20 patients with repeat CRS + intraperitoneal chemotherapy (IPC) for isolated peritoneal tumour recurrence of all origins. Five- and 10-year overall survival (OS) rates were 72.5% and 58.1% respectively.

Even though they studied selected groups of patients, the studies by Sugarbaker and Brouquet underline the possibility of highly favourable outcomes and even long-term survival in palliative patients with recurrence of peritoneal carcinomatosis.

In this context, the study by Kianmanesh *et al*[12] included 43 patients with PC of colorectal cancer origin who underwent CRS/HIPEC and specifically evaluated the role of simultaneous liver resection. They concluded that patients with colorectal PC, iterative CRS and HIPEC achieved appreciable long-term survival and that liver metastasis resection did not negatively influence the postoperative outcomes. However, they did not specify whether an extended vascular resection was performed or if liver resections were performed in cases of metachronous LM.

Achieving complete cytoreduction in most cases is challenging and implies an aggressive approach combining major surgical procedures not exempt from complications. In selected cases, as in the one presented here, the option of re-do surgery for liver metastasis is feasible. Even extended vascular resection is acceptable after CRS/HIPEC and can be considered as a potentially curative treatment option. Early detection of tumour recurrence through a close follow-up is essential, as well as a multidisciplinary assessment of patient selection. The patients should then be referred to a centre specialized in the treatment of peritoneal and liver metastases. In the present case, staged resection of both metastatic sites achieved long-term survival for a young female patient. To our knowledge, this is this first report on liver resection due to metachronous liver metastases following CRS and HIPEC.

**COMMENTS**

***Case characteristics***

A 35-year-old patient with liver recurrent disease after an extended cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) procedure.

***Clinical diagnosis***

Abdominal MRI diagnosed the liver recurrence in the follow-up.

***Differential diagnosis***

There is no possible differential diagnosis in this case.

***Laboratory diagnosis***

All labs were within normal limits.

***Imaging diagnosis***

MRI showed a solid tumor in segment 1 of the liver.

***Pathological diagnosis***

pT4a pN2a (4/22) cM0 poorly differentiated adenocarcinoma

***Treatment***

Complete surgical excision of lesion.

***Related reports***

There are currently no other reports of surgical excision of a liver metastasis in the caudate lobe two years after a Cytoreductive surgery.

***Experiences and lessons***

The report is good example of patient tailored treatment in cases where guidelines are missing or suggest only palliative or best supportive care. It is also novel to perform such an extensive surgery after cytoreductive surgery and HIPEC.

***Peer-review***

The paper is well written.

**REFERENCES**

1 **Lemmens VE**, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer* 2011; **128**: 2717-2725 [PMID: 20715167 DOI: 10.1002/ijc.25596]

2 **Esquivel J**. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. *J Gastrointest Oncol* 2016; **7**: 72-78 [PMID: 26941985]

3 **Esquivel J**, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. *Ann Surg Oncol* 2007; **14**: 128-133 [PMID: 17072675 DOI: 10.1245/s10434-006-9185-7]

4 **Verwaal VJ**, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003; **21**: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]

5 **Franko J**, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer* 2010; **116**: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]

6 **Piso P**, Arnold D, Glockzin G. Challenges in the multidisciplinary management of stage IV colon and rectal cancer. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 317-326 [PMID: 25192718 DOI: 10.1586/17474124.2015.957273]

7 **Piso P**, Arnold D. Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. *Dtsch Ärzteblatt Int* 2011; **108**: 802–808

8 **Elias D**, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2010; **28**: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9285]

9 **Koppe MJ**, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. *Ann Surg* 2006; **243**: 212-222 [PMID: 16432354 DOI: 10.1097/01.sla.0000197702.46394.16]

10 **Cavaliere F**, De Simone M, Virzì S, Deraco M, Rossi CR, Garofalo A, Di Filippo F, Giannarelli D, Vaira M, Valle M, Pilati P, Perri P, La Pinta M, Monsellato I, Guadagni F. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. *Eur J Surg Oncol* 2011; **37**: 148-154 [PMID: 21093205 DOI: 10.1016/j.ejso.2010.10.014]

11 **Mirnezami R**, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. *World J Gastroenterol* 2014; **20**: 14018-14032 [PMID: 25320542 DOI: 10.3748/wjg.v20.i38.14018]

12 **Kianmanesh R**, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg* 2007; **245**: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]

13 **Brouquet A**, Goéré D, Lefèvre JH, Bonnet S, Dumont F, Raynard B, Elias D. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome. *Ann Surg Oncol* 2009; **16**: 2744-2751 [PMID: 19626375 DOI: 10.1245/s10434-009-0611-5]

14 **Vassos N**, Förtsch T, Aladashvili A, Hohenberger W, Croner RS. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. *World J Surg Oncol* 2016; **14**: 42 [PMID: 26912149 DOI: 10.1186/s12957-016-0804-x]

15 **Bijelic L**, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. *J Surg Oncol* 2008; **98**: 295-299 [PMID: 18726900 DOI: 10.1002/jso.21084]

16 **Maggiori L**, Goéré D, Viana B, Tzanis D, Dumont F, Honoré C, Eveno C, Elias D. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. *Ann Surg* 2013; **258**: 116-121 [PMID: 23207243 DOI: 10.1097/SLA.0b013e3182778089]

17 **Verwaal VJ**, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. *Ann Surg Oncol* 2004; **11**: 375-379 [PMID: 15070596 DOI: 10.1245/ASO.2004.08.014]

18 **Elias D**, Faron M, Iuga BS, Honoré C, Dumont F, Bourgain JL, Dartigues P, Ducreux M, Goéré D. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. *Ann Surg* 2015; **261**: 157-163 [PMID: 24509197 DOI: 10.1097/SLA.0000000000000582]

19 **de Cuba EM**, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. *Cancer Treat Rev* 2013; **39**: 321-327 [PMID: 23244778 DOI: 10.1016/j.ctrv.2012.11.003]

20 **Esquivel J**, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. *Ann Surg* 2001; **234**: 198-205 [PMID: 11505065 DOI: 10.1097/00000658-200108000-00009]

**P-Reviewer:** Hoskovec D, Levine EA, Peng SY, Tentes AA, van Oudheusden TR **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): B, B

Grade C (Good): C


Grade D (Fair): 0

Grade E (Poor): 0


**Table 1 History and detail surgical treatment of our patient´s disease**

|  |  |  |
| --- | --- | --- |
| **Time point** | **Diagnosis** | **Procedure** |
| 2011 | Stenotic tumour of the cecum | Right Colectomy  Adjuvant chemotherapy (12 Cycles with folinic acid, 5-fluorouracil, and oxaliplatin) |
| 2012 | Peritoneal carcinomatosis  *PCI = 14* | CRS *(CCR-0)*  Total parietal and diaphragmatic Peritonectomy  Proctocolectomy with end ileostomy  Terminal ileum resection  Splenectomy  Omentectomy  Hysterectomy  Bilateral salpingo-oophorectomy  HIPEC  43.8 mg Mitomycin C intraperitoneal (1 h) |
| 2014 | Liver metastases segment I with IVC infiltration | Resection of liver segment I  Partial resection of IVC with prosthetic graft interposition  Cholecystectomy  Partial adrenalectomy |
| 2016 | No evidence of neoplastic disease |  |

PCI: Peritoneal cancer Index.



**Figure 1 MRI shows an isolated liver metastasis in caudate lobe of the liver.**



**Figure 2** **Distal inferior vena cava**. A: Tumor mass infiltrating the inferior vena cava (ICV) at the bifurcation of the renal veins (vessel loop); B: Vascular interposition graft after partial resection of the IVC.